ADAP
Price
$0.28
Change
+$0.01 (+3.70%)
Updated
Jul 14 closing price
Capitalization
74.48M
22 days until earnings call
ORMP
Price
$2.13
Change
-$0.00 (-0.00%)
Updated
Jul 14 closing price
Capitalization
87.01M
29 days until earnings call
Interact to see
Advertisement

ADAP vs ORMP

Header iconADAP vs ORMP Comparison
Open Charts ADAP vs ORMPBanner chart's image
Adaptimmune Therapeutics
Price$0.28
Change+$0.01 (+3.70%)
Volume$563.62K
Capitalization74.48M
Oramed Pharmaceuticals
Price$2.13
Change-$0.00 (-0.00%)
Volume$56.79K
Capitalization87.01M
ADAP vs ORMP Comparison Chart in %
Loading...
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADAP vs. ORMP commentary
Jul 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADAP is a Buy and ORMP is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 15, 2025
Stock price -- (ADAP: $0.28 vs. ORMP: $2.13)
Brand notoriety: ADAP and ORMP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADAP: 52% vs. ORMP: 76%
Market capitalization -- ADAP: $74.48M vs. ORMP: $87.01M
ADAP [@Biotechnology] is valued at $74.48M. ORMP’s [@Biotechnology] market capitalization is $87.01M. The market cap for tickers in the [@Biotechnology] industry ranges from $305.86B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADAP’s FA Score shows that 0 FA rating(s) are green whileORMP’s FA Score has 0 green FA rating(s).

  • ADAP’s FA Score: 0 green, 5 red.
  • ORMP’s FA Score: 0 green, 5 red.
According to our system of comparison, ORMP is a better buy in the long-term than ADAP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADAP’s TA Score shows that 5 TA indicator(s) are bullish while ORMP’s TA Score has 2 bullish TA indicator(s).

  • ADAP’s TA Score: 5 bullish, 5 bearish.
  • ORMP’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, ADAP is a better buy in the short-term than ORMP.

Price Growth

ADAP (@Biotechnology) experienced а +16.55% price change this week, while ORMP (@Biotechnology) price change was -1.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +10.48%. For the same industry, the average monthly price growth was +21.25%, and the average quarterly price growth was +31.32%.

Reported Earning Dates

ADAP is expected to report earnings on Nov 05, 2025.

ORMP is expected to report earnings on Nov 14, 2025.

Industries' Descriptions

@Biotechnology (+10.48% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ORMP($87M) has a higher market cap than ADAP($74.5M). ORMP YTD gains are higher at: -11.983 vs. ADAP (-47.837). ORMP has higher annual earnings (EBITDA): -21.53M vs. ADAP (-50.18M). ORMP has more cash in the bank: 131M vs. ADAP (59.6M). ORMP has less debt than ADAP: ORMP (301K) vs ADAP (48.7M). ADAP has higher revenues than ORMP: ADAP (180M) vs ORMP (2M).
ADAPORMPADAP / ORMP
Capitalization74.5M87M86%
EBITDA-50.18M-21.53M233%
Gain YTD-47.837-11.983399%
P/E RatioN/A20.91-
Revenue180M2M9,000%
Total Cash59.6M131M45%
Total Debt48.7M301K16,179%
FUNDAMENTALS RATINGS
ADAP vs ORMP: Fundamental Ratings
ADAP
ORMP
OUTLOOK RATING
1..100
458
VALUATION
overvalued / fair valued / undervalued
1..100
52
Fair valued
57
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9794
PRICE GROWTH RATING
1..100
6562
P/E GROWTH RATING
1..100
10049
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ADAP's Valuation (52) in the Biotechnology industry is in the same range as ORMP (57) in the Pharmaceuticals Other industry. This means that ADAP’s stock grew similarly to ORMP’s over the last 12 months.

ADAP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ORMP (100) in the Pharmaceuticals Other industry. This means that ADAP’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's SMR Rating (94) in the Pharmaceuticals Other industry is in the same range as ADAP (97) in the Biotechnology industry. This means that ORMP’s stock grew similarly to ADAP’s over the last 12 months.

ORMP's Price Growth Rating (62) in the Pharmaceuticals Other industry is in the same range as ADAP (65) in the Biotechnology industry. This means that ORMP’s stock grew similarly to ADAP’s over the last 12 months.

ORMP's P/E Growth Rating (49) in the Pharmaceuticals Other industry is somewhat better than the same rating for ADAP (100) in the Biotechnology industry. This means that ORMP’s stock grew somewhat faster than ADAP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADAPORMP
RSI
ODDS (%)
Bullish Trend 2 days ago
81%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 7 days ago
78%
Bullish Trend 13 days ago
82%
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 19 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
QGLHF0.07N/A
N/A
Qingling Motors Ltd.
CTTH0.03N/A
N/A
CTT Pharmaceutical Holdings, Inc.
HTSUF28.94N/A
N/A
Hisamitsu Pharmaceutical Co., Ltd.
AFSIA13.25N/A
N/A
AmTrust Financial Services, Inc.
RKUNY5.36-0.03
-0.50%
Rakuten Group Inc.

ADAP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADAP has been loosely correlated with AKBA. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ADAP jumps, then AKBA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADAP
1D Price
Change %
ADAP100%
+4.62%
AKBA - ADAP
41%
Loosely correlated
+1.02%
ORMP - ADAP
36%
Loosely correlated
-0.23%
AUTL - ADAP
33%
Poorly correlated
+7.29%
CSLLY - ADAP
32%
Poorly correlated
+0.99%
AXON - ADAP
31%
Poorly correlated
+2.83%
More

ORMP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORMP has been loosely correlated with BTAI. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ORMP jumps, then BTAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORMP
1D Price
Change %
ORMP100%
-0.23%
BTAI - ORMP
44%
Loosely correlated
+2.54%
INO - ORMP
44%
Loosely correlated
N/A
MBIO - ORMP
44%
Loosely correlated
-9.70%
VERV - ORMP
44%
Loosely correlated
N/A
ZNTL - ORMP
43%
Loosely correlated
+2.26%
More